



Yomeishu 次のすこやかさへ、一步一步



May 13, 2025

Company name:	YOMEISHU SEIZO CO., LTD.
Name of representative:	Hideo Tanaka, Representative Director, President and COO
Securities code:	2540; TSE Prime Market
For inquiries:	Akira Igawa, Senior Executive Officer and General Manager, Corporate Planning Department
Telephone:	+81-3-3462-8138

(Correction) Notice Concerning Secondary Distribution of Shares, Change in the Largest Major Shareholder and Any Other Associated Company, and Cancellation of a Capital and Business Alliance Agreements

YOMEISHU SEIZO CO., LTD. (the “Company”) hereby announces that there have been corrections made to the “Notice Concerning Secondary Distribution of Shares, Change in the Largest Major Shareholder and Any Other Associated Company, and Cancellation of a Capital and Business Alliance Agreement” disclosed on March 24, 2025, as described below.

The corrections are underlined.

1. Reason for correction

After receiving a report that all shares of common stock of the Company held by Taisho Pharmaceutical Holdings Co., Ltd. (“Taisho Pharmaceutical”) had been transferred to Yuzawa KK (“Yuzawa”), the Company understood that Yuzawa would fall under “Any Other Associated Company” of the Company as prescribed in Article 8, Paragraph 17, Item (4) of the Financial Statements Regulation, and made a timely disclosure on March 24, 2025. However, the Company has corrected this as the result of asking Yuzawa about the purpose of holding and other matters.

2. Details of correction

[Before correction]

II. Change in the Largest Major Shareholder and Any Other Associated Company

1. Particulars of change

As the result of this transfer, Taisho Pharmaceutical will no longer fall under the largest major shareholder and any other associated company of the Company, as described below. By acquiring 3,300,000 shares of common stock of the Company from Taisho Pharmaceutical, Yuzawa will hold 23.69% of the total number of issued shares of the Company (as of December 31, 2024, the Company's own shares are excluded. A percentage of voting rights of 23.73%), and will fall the largest major shareholder and any other associated company of the Company.

[After correction]

II. Change in the Largest Major Shareholder and Any Other Associated Company

1. Particulars of change

As the result of this transfer, Taisho Pharmaceutical will no longer fall under the largest major shareholder and

any other associated company of the Company, as described below. By acquiring 3,300,000 shares of common stock of the Company from Taisho Pharmaceutical, Yuzawa will hold 23.69% of the total number of issued shares of the Company (as of December 31, 2024, the Company's own shares are excluded. A percentage of voting rights of 23.73%), and will fall under the largest major shareholder of the Company.

[Before correction]

2. Outline of the largest major shareholder and any other associated company changed

(1) Shareholder that will newly fall under the largest major shareholder and any other associated company

(1) Name	Yuzawa KK
(2) Location	2-19-15 Shibuya, Shibuya-ku, Tokyo
(3) Job title and name of representative	Akihito Saigusa, Representative
(4) Description of business	Investment business; holding, management, and buying and selling of securities, etc.; buying and selling, lease, and management of real estate; management consulting; and any other business associated with, and related to, the business mentioned above
(5) Share capital	10 million yen
(6) Date of establishment	March 9, 2022
(7) Major shareholders and ownership ratios	Not disclosed due to the intention of the counterparty.
(8) Relationship between the listed company and the relevant company	
Capital relationship	There is no capital relationship to be disclosed.
Personnel relationship	There is no capital relationship to be disclosed.
Business relationship	There is no capital relationship to be disclosed.
Related party relationship	There is no capital relationship to be disclosed.
(9) Net assets	Not disclosed due to the intention of the counterparty.
(10) Total assets	Not disclosed due to the intention of the counterparty.

[After correction]

2. Outline of the largest major shareholder and any other associated company changed

(1) Shareholder that will newly fall under the largest major shareholder

(1) Name	Yuzawa KK
(2) Location	2-19-15 Shibuya, Shibuya-ku, Tokyo
(3) Job title and name of representative	Akihito Saigusa, Representative
(4) Description of business	Investment business; holding, management, and buying and selling of securities, etc.; buying and selling, lease, and management of real estate; management consulting; and any other business associated with, and related to, the business mentioned above
(5) Share capital	10 million yen
(6) Date of establishment	March 9, 2022
(7) Major shareholders and ownership ratios	Not disclosed due to the intention of the counterparty.
(8) Relationship between the listed company and the relevant company	
Capital relationship	There is no capital relationship to be disclosed.
Personnel relationship	There is no capital relationship to be disclosed.
Business relationship	There is no capital relationship to be disclosed.
Related party relationship	There is no capital relationship to be disclosed.
(9) Net assets	Not disclosed due to the intention of the counterparty.
(10) Total assets	Not disclosed due to the intention of the counterparty.

[Before correction]

3. Number and ratio of voting rights (shares) held by the relevant shareholders before and after the change

(1) Yuzawa

	Attribute	Number (ratio) of voting rights			Large shareholder ranking
		Direct ownership	Indirect ownership	Total	
Before change	—	—	—	—	—
After change	The largest major shareholder and <u>any other associated company</u>	33,000 voting rights (23.73%)	— voting rights (—%)	33,000 voting rights (23.73%)	1

[After correction]

3. Number and ratio of voting rights (shares) held by the relevant shareholders before and after the change

(1) Yuzawa

	Attribute	Number (ratio) of voting rights			Large shareholder ranking
		Direct ownership	Indirect ownership	Total	
Before change	—	—	—	—	—
After change	The largest major shareholder	33,000 voting rights (23.73%)	— voting rights (—%)	33,000 voting rights (23.73%)	1

[Before correction]

5. Change of unlisted parent company, etc. subject to disclosure

As the result of this transfer, Taisho Pharmaceutical will no longer fall under the unlisted parent company, etc. subject to disclosure. Meanwhile, Yuzawa will fall under the unlisted parent company, etc. subject to disclosure.

[After correction]

5. Change of unlisted parent company, etc. subject to disclosure

As the result of this transfer, Taisho Pharmaceutical will no longer fall under the unlisted parent company, etc. subject to disclosure.